Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs MEDI 570 (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Adverse reactions
- 26 Apr 2016 Status changed from not yet recruiting to recruiting.
- 14 Apr 2016 Planned primary completion date changed from 1 Nov 2017 to 1 May 2018.
- 12 Apr 2016 Planned initiation date changed from 1 Nov 2015 to 1 Jul 2016.